trial

Add-On Therapy to Risperidonein Schizophrenia

NCTId NCT01189006
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 2, Phase 3 · Completed
Enrollment 161 (actual)
Sponsored by National Cheng-Kung University Hospital
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 2, Phase 3
Status
Completed
Enrollment
161 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2005-01
Primary completion
2008-12
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Dextromethorphan

Sponsors

National Cheng-Kung University HospitalLead Sponsor

Investigators

1
Ru-Band Lu, MDPrincipal Investigator

Sites

1 total
Tainan, Taiwan

Linked catalysts

1
Add-On Therapy to Risperidonein Schizophrenia — primary completion2008-12

Facts & assertions

4 sourced
Enrollment
161
Phase
PHASE2,PHASE3
Primary Completion Date
2008-12
Status
COMPLETED
relationships
The graph out of here
drug
Dextromethorphan
drug
lead_sponsor
National Cheng-Kung University Hospital
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Ru-Band Lu, MD
person